GNI Group
2160.TTSE GROWTHPharmaceutical
Filed as GNI Group Ltd. (2022-08–2026-08)
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥26.8bn | ¥23.6bnr | ¥26.0bnr | ¥17.4bnr | ¥12.7bnr | ¥9.8bn |
| Operating income | −¥3.5bn | ¥1.4bnr | ¥13.1bn | ¥1.4bn | ¥1.6bn | — |
| Net income (owners) | −¥4.2bn | ¥1.1bnr | ¥8.1bnr | ¥388mr | ¥1.1bnr | ¥1.3bn |
| Total assets | ¥83.8bn | ¥71.9bnr | ¥64.3bnr | ¥33.9bnr | ¥30.3bnr | ¥23.2bn |
| Net assets / equity | ¥51.8bn | ¥39.7bnr | ¥36.5bnr | ¥19.8bn | ¥19.3bn | ¥12.8bn |
| Operating cash flow | −¥2.4bn | −¥3.2bnr | ¥6.5bnr | ¥393mr | ¥552mr | ¥1.4bn |
| EPS (basic) | ¥-80.9 | ¥21.96 | ¥169.5 | ¥8.19 | ¥22.72 | ¥28.96 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 6
| Period | Form | Figures |
|---|---|---|
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 89 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 111 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 111 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 89 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 111 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 111 figures · EDINET |
32 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Medical Device | ¥7.7bn | ¥533m |
| Pharmaceutical | ¥19.2bn | −¥4.0bn |
| Total | ¥26.8bn | −¥3.5bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.